3 Global Generics and Active Ingredients Maker, Branded Formulations Company and Research-Led Pharma Company Stocks With a Strong Future Roadmap: Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals
- October 28, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals: ROE of 11.1% to 28.1% and FY22 to FY26 revenue CAGR of 8.7% to 12.3%. Prices as of 27 Oct 2026.
Quick Answer
The three international generics and formulation stocks to watch are Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals. Their return on equity ranges from 11.1% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 12.3%. Glenmark Pharmaceuticals has the highest return on equity at 28.1%, while Dr. Reddy’s Laboratories has the fastest revenue growth at 12.3% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
International generics and formulation stocks let investors follow companies that serve a growing part of the Indian economy. Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals cover a global generics and active ingredients maker, a branded formulations company and a research-led pharma company.
This list covers three international generics and formulation stocks with complete current figures: Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are International Generics and Formulation Stocks?
International generics and formulation stocks are listed pharmaceutical companies that make generics, active ingredients and branded formulations for India, North America, Europe and other markets. Their earnings depend on product launches, regulatory approvals, pricing and currency.
International Generics and Formulation Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Dr. Reddy’s Laboratories | 1,310 | 103,667 | 32.6 | 36.0 | 11.1 | 0.20 |
| Emcure Pharmaceuticals | 1,875.2 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Glenmark Pharmaceuticals | 2,265.7 | 60,103 | 33.4 | 35.7 | 28.1 | 0.06 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing international generics and formulation stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do International Generics and Formulation Stocks Have a Strong Roadmap in India?
International generics and formulation stocks have a strong roadmap in India because new product launches, rising healthcare spending and expanding exports keep widening the market for Indian pharmaceutical companies.
- Product launches. New approvals broaden the range.
- Domestic brands. Branded medicines build steady demand.
- Exports. Overseas markets add scale.
Why Dr. Reddy’s Laboratories Features Among These International Generics and Formulation Stocks
Among the international generics and formulation stocks on this list, Dr. Reddy’s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.
Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.
Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.
Why Emcure Pharmaceuticals Features Among These International Generics and Formulation Stocks
Among the generics, branded formulations and innovation shares on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Glenmark Pharmaceuticals Features Among These International Generics and Formulation Stocks
Among the three companies on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.
In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%.
Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.
Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.
Dr. Reddy’s Laboratories vs Emcure Pharmaceuticals vs Glenmark Pharmaceuticals on Key Financials
The table below sets the three international generics and formulation stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Dr. Reddy’s Laboratories | 22,030 | 35,059 | 12.3% | 4,158 | 11.9% |
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Glenmark Pharmaceuticals | 12,472 | 17,443 | 8.7% | 1,362 | 7.8% |
Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Dr. Reddy’s Laboratories combines the largest FY26 revenue at Rs 35,059 crore with the fastest revenue growth, a 12.3% compound annual rate.
Key Risks to Check Before Investing in International Generics and Formulation Stocks
Every theme carries risks that deserve a check before any decision. For these international generics and formulation stocks, the main points are:
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter international generics and formulation stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on International Generics and Formulation Stocks
International generics and formulation stocks reward investors who follow demand trends, order books and margins together. Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals each have a clear plan to grow. Based on the 27 October 2026 close, Dr. Reddy’s Laboratories trades at Rs 1,310, Emcure Pharmaceuticals at Rs 1,875.2 and Glenmark Pharmaceuticals at Rs 2,265.7.
Download the Univest iOS App or Univest Android App to track international generics and formulation stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are international generics and formulation stocks?
Ans. International generics and formulation stocks are listed pharmaceutical companies that make generics, active ingredients and branded formulations for India, North America, Europe and other markets. Their earnings depend on product launches, regulatory approvals, pricing and currency. This list looks at three of them, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which international generics and formulation stocks are covered in this list?
Ans. This list covers Dr. Reddy’s Laboratories, Emcure Pharmaceuticals and Glenmark Pharmaceuticals. Based on the 27 October 2026 close, Dr. Reddy’s Laboratories traded at Rs 1,310, Emcure Pharmaceuticals at Rs 1,875.2 and Glenmark Pharmaceuticals at Rs 2,265.7. Their return on equity ranges from 11.1% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 12.3%.
Why do international generics and formulation stocks have a strong future roadmap in India?
Ans. International generics and formulation stocks have a strong roadmap in India because new product launches, rising healthcare spending and expanding exports keep widening the market for Indian pharmaceutical companies. The main drivers are as follows. Product launches. New approvals broaden the range. Domestic brands. Branded medicines build steady demand. Exports. Overseas markets add scale. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Dr. Reddy’s Laboratories performed financially?
Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Glenmark Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.
What risks should investors check before buying international generics and formulation stocks?
Ans. Investors should check a few risks before buying international generics and formulation stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of international generics and formulation stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
